All In Biotech

Drug Trial Radar · NCT06608134

Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Knee Osteoarthritis

Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for

Last checked: Nov 20, 2026Latest source record: Sep 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Oct 1, 2024

Primary completion

Oct 1, 2028

Study completion Oct 1, 2029

Sponsor

Lead sponsor
R3 Medical ResearchIndustry
Sponsor type
Industry
First posted
Sep 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Pilot Study which is randomized, prospective, open label, dose escalation, non-controlled evaluating safety and feasibility of intra-articular Wharton's Jelly (WJ) allograft will be evaluated in patients suffering with knee osteoarthritis. The participants will be randomized to one of three dosing treatment arms that will consist of one intra-articular knee injection containing either low dose, medium dose or high dose WJ allograft tissue.

Conditions

  • Osteoarthritis, Knee

Interventions

  • Umbilical Cord Wharton's Jelly Allograft Intra-articular Knee InjectionBiological

    Direct injection of biologic into the knee joint.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. C Reactive ProteinTime frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year
  2. Erythrocyte Sedimentation RateTime frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year
  3. Alanine TransaminaseTime frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year
  4. Aspartate TransaminaseTime frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year
  5. Alkaline PhosphataseTime frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year
  6. AlbuminTime frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year
  7. CreatinineTime frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year
  8. Blood Urea NitrogenTime frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • R3 Anti Aging Scottsdale

    Scottsdale, Arizona · Recruiting

  • R3 Anti Aging Beverly Hills

    Beverly Hills, California · Recruiting

  • Optimal Medical Group

    Fresno, California · Recruiting

  • Scheer Medical Wellness

    New York, New York · Recruiting

  • Dr. Duc (Steve) Le, MD

    Cleveland, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.